Communicating about chemotherapy-induced nausea and vomiting: A comparison of patient and provider perspectives

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 10, Issue 2, 2012, Pages 149-157

  Salsman, John M ^a   Grunberg, Steven M ^b   Beaumont, Jennifer L ^a   Rogers, Miriam ^c   Paul, Diane ^d   Clayman, Marla L ^a   Cella, David ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^c GREENVILLE HOSPITAL SYSTEM   (United States)

^d National Comprehensive Cancer Network   (United States)

Author keywords

Chemotherapy; Communication; Emesis; Nausea; Perception

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; ADVANCED PRACTICE NURSE; ARTICLE; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; DRUG USE; FEMALE; HEALTH CARE QUALITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; MULTIPLE CYCLE TREATMENT; ONCOLOGIST; PATIENT ATTITUDE; PHYSICIAN;

EID: 84856933060     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2012.0018     Document Type: Article

References (25)

1. Griffin AM, Butow PN, Coates AS, et al. On the receiving end. V: patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol 1996;7:189-195. (Pubitemid 26094884)
2. Roscoe JA, Morrow GR, Hickok JT, et al. Nausea and vomiting remain a significant clinical problem. J Pain Symptom Manage 2000;20:113-121.
3. Cohen L, Moor C, Eisenberg P, et al. Chemotherapy-induced nausea and vomiting--incidence and impact on patient quality of life at community oncology settings. Support Care Cancer 2007;15:497-503. (Pubitemid 46570778)
4. Bloechl-Daum B, Deuson RR, Mavros P, et al. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 2006;24:4472-4478. (Pubitemid 46630986)
5. Ettinger DS, Armstrong DK, Barbour S, et al. NCCN Clinical Practice Guidelines in Oncology: Antiemesis. Version 1, 2012. Available at: http://www.nccn.org/professionals/physician-gls/pdf/antiemesis.pdf. Accessed January 4, 2012.
6. Schwartzberg L. Chemotherapy-induced nausea and vomiting: state of the art in 2006. J Support Oncol 2006;4:3-8. (Pubitemid 43338178)
7. Grunberg SM, Deuson RR, Mavros P, et al. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 2004;100:2261-2268. (Pubitemid 38580348)
8. Gralla RJ, Osoba D, Kris MG, et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol 1999;17:2971-2994. (Pubitemid 29415258)
9. Roila F, Donati D, Tamberi S, et al. Delayed emesis: incidence, pattern, prognostic factors and optimal treatment. Support Care Cancer 2002;10:88-95. (Pubitemid 36056305)
10. Warr DG, Grunberg SM, Gralla RJ, et al. The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: pooled data from 2 randomised, double-blind, placebo controlled trials. Eur J Cancer 2005;41:1278-1285. (Pubitemid 40813003)
11. Passik SD, Kirsh KL, Rosenfeld B, et al. The changeable nature of patients' fears regarding chemotherapy - implications for palliative care. J Pain Symptom Manage 2001;21:113-120. (Pubitemid 32156941)
12. Navari RM. Overview of the updated antiemetic guidelines for chemotherapy-induced nausea and vomiting. Community Oncology 2007;4(Suppl 1):3-11. (Pubitemid 46724235)
13. Grunberg SM, Boutin N, Ireland A, et al. Impact of nausea/vomiting on quality of life as a visual analogue scale-derived utility score. Support Care Cancer 1996;4:435-439. (Pubitemid 126470385)
14. Sun CC, Bodurka DC, Donato ML, et al. Patient preferences regarding side effects of chemotherapy for ovarian cancer: do they change over time? Gynecol Oncol 2002;87:118-128. (Pubitemid 36027111)
15. Grunberg SM, Warr D, Gralla RJ, et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity - state of the art. Support Care Cancer 2011;19(Suppl 1):S43-47.
16. Passik SD, Kirsh KL, Donaghy K, et al. Patient-related barriers to fatigue communication: initial validation of the fatigue management barriers questionnaire. J Pain Symptom Manage 2002;24:481-493. (Pubitemid 36120424)
17. Burke T, Wisniewski T, Ernst F. Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting. Support Care Cancer 2011;19:131-140.
18. Tina Shih YC, Xu Y, Elting LS. Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy. Cancer 2007;110:678-685. (Pubitemid 47106159)
19. Schrag D, Hanger M. Medical oncologists' views on communicating with patients about chemotherapy costs: a pilot survey. J Clin Oncol 2007;25:233-237. (Pubitemid 350003040)
20. Molassiotis A, Brearley S, Stamataki Z. Use of antiemetics in the management of chemotherapy-related nausea and vomiting in current UK practice. Support Care Cancer 2011;19:949-956.
21. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-497. (Pubitemid 41127293)
22. Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 2006;24:2932-2947. (Pubitemid 46630595)
23. ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health Syst Pharm 1999;56:729-764.
24. Mertens WC, Higby DJ, Brown D, et al. Improving the care of patients with regard to chemotherapy-induced nausea and emesis: the effect of feedback to clinicians on adherence to antiemetic prescribing guidelines. J Clin Oncol 2003;21:1373-1378. (Pubitemid 46606418)
25. Davis K, Yount S, Del Ciello K, et al. An innovative symptom monitoring tool for people with advanced lung cancer: a pilot demonstration. J Support Oncol 2007;5:381-387. (Pubitemid 47565043)